A shortcut to the lysosome: The mannose-6-phosphate-independent pathway

Molecular Genetics and Metabolism

Volumn 107, Issue 3, 2012, Pages 257-266

  Coutinho, Maria Francisca ^a,b,c   Prata, Maria João ^b,c   Alves, Sandra ^a  

^a NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c Faculty of Sciences   (Portugal)

Author keywords

Action myoclonus renal failure syndrome (AMRF); Lysosomal integral membrane protein 2 (LIMP2); Mannose 6 phosphate dependent pathway; Sortilin neurotensin receptor 3

Indexed keywords

APOLIPOPROTEIN; CATHEPSIN D; CATHEPSIN H; CHITOTRIOSIDASE; GLUCOSYLCERAMIDASE; HYDROLASE; LIPOPROTEIN; LIPOPROTEIN LIPASE; LYSOSOMAL INTEGRAL MEMBRANE PROTEIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MANNOSE 6 PHOSPHATE; MEMBRANE PROTEIN; NEUROTENSIN; NEUROTENSIN RECEPTOR; NEUROTROPHIN RECEPTOR P75; POTASSIUM CHANNEL KCNQ1; PROSAPOSIN; PROTEIN SOR CS1; PROTEIN SOR CS2; PROTEIN SOR CS3; PROTEIN SOR LA; RAP PROTEIN; SOMATOMEDIN B RECEPTOR; SORTILIN; SPHINGOLIPID; SPHINGOLIPID ACTIVATOR PROTEIN; SPHINGOMYELIN PHOSPHODIESTERASE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROPLAKIN;

ACTION MYOCLONUS RENAL FAILURE SYNDROME; AMYOTROPHIC LATERAL SCLEROSIS; CARDIOVASCULAR RISK; CELL FUNCTION; CELL TRANSPORT; DEMYELINATING NEUROPATHY; FAMILIAL DISEASE; FOCAL GLOMERULOSCLEROSIS; FRONTOTEMPORAL DEMENTIA; GAUCHER DISEASE; GENE; GENE MUTATION; GENETIC ASSOCIATION; GM2 GANGLIOSIDOSIS; GOLGI COMPLEX; HEART INFARCTION; HUMAN; LYSOSOME; LYSOSOME STORAGE DISEASE; MAMMAL CELL; METACHROMATIC LEUKODYSTROPHY; MYOCLONUS EPILEPSY; NIEMANN PICK DISEASE; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; ROUGH ENDOPLASMIC RETICULUM; SCARB2 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TRANS GOLGI NETWORK;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; CARRIER PROTEINS; CATHEPSINS; G(M2) ACTIVATOR PROTEIN; GLUCOSYLCERAMIDASE; HUMANS; LYSOSOMAL STORAGE DISEASES; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; LYSOSOMES; MANNOSEPHOSPHATES; NEUROTENSIN; PROTEIN TRANSPORT; RECEPTOR, IGF TYPE 2; RECEPTORS, SCAVENGER; SAPOSINS; SPHINGOMYELIN PHOSPHODIESTERASE; TRANS-GOLGI NETWORK;

MAMMALIA;

EID: 84867898166     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2012.07.012     Document Type: Review

References (97)

1. Braukle T., Bonifacino J.S. Sorting of lysosomal proteins. Biochim. Biophys. Acta 2008, 1793:605-614.
2. Ni X., Canuel M., Morales C.R. The sorting and trafficking of lysosomal proteins. Histol. Histopathol. 2006, 21:899-913.
3. Rijnboutt S., Aerts H.M., Geuze H.J., Tager J.M., Strous G.J. Mannose 6-phosphate-independent membrane association of cathepsin D, glucocerebrosidase, and sphingolipid-activating protein in HepG2 cells. J. Biol. Chem. 1991, 266:4862-4868.
4. Rijnboutt S., Kal A.J., Geuze H.J., Aerts H., Strous G.J. Mannose 6-phosphate-independent targeting of cathepsin D to lysosomes in HepG2 cells. J. Biol. Chem. 1991, 266:23586-23592.
5. Tsuji A., Omura K., Suzuki Y. I-cell disease: evidence for a mannose 6-phosphate independent pathway for translocation of lysosomal enzymes in lymphoblastoid cells. Clin. Chim. Acta 1988, 176:115-121.
6. Reczek D., Schwake M., Schröder J., Hughes H., Blanz J., Jin X., Brondyk W., Van Patten S., Edmunds T., Saftig P. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell 2007, 131:770-783.
7. Petersen C.M., Nielsen M.S., Nykjaer A., Jacobsen L., Tommerup N., Rasmussen H.H., Roigaard H., Gliemann J., Madsen P., Moestrup S.K. Molecular identification of a novel candidate sorting receptor purified from human brain by receptor-associated protein affinity chromatography. J. Biol. Chem. 1997, 272:3599-3605.
8. Mazella J., Zsürger N., Navarro V., Chabry J., Kaghad M., Caput D., Ferrara P., Vita N., Gully D., Maffrand J.P., Vincent J.P. The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. J. Biol. Chem. 1998, 273:26273-26276.
9. Nielsen M.S., Jacobsen C., Olivecrona G., Gliemann J., Petersen C.M. Sortilin/neurotensin receptor-3 binds and mediates degradation of lipoprotein lipase. J. Biol. Chem. 1999, 274:8832-8836.
10. Lefrancois S., Zeng J., Hassan A.J., Canuel M., Morales C.R. The lysosomal trafficking of sphingolipid activator proteins (SAPs) is mediated by sortilin. EMBO J. 2003, 22:6430-6437.
11. Canuel M., Korkidakis A., Konnyu K., Morales C.R. Sortilin mediates the lysosomal targeting of cathepsins D and H. Biochem. Biophys. Res. Commun. 2008, 373:292-297.
12. Calvo D., Dopazo J., Vega M.A. The CD36, CLA-1 (CD36L1), and LIMPII (CD36L2) gene family: cellular distribution, chromosomal location, and genetic evolution. Genomics 1995, 25:100-106.
13. Berkovic S.F., Dibbens L.M., Oshlack A., Silver J.D., Katerelos M., Vears D.F., Lüllmann-Rauch R., Blanz J., Zhang K.W., Stankovich J., Kalnins R.M., Dowling J.P., Andermann E., Andermann F., Faldini E., D'Hooge R., Vadlamudi L., Macdonell R.A., Hodgson B.L., Bayly M.A., Savige J., Mulley J.C., Smyth G.K., Power D.A., Saftig P., Bahlo M. Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis. Am. J. Hum. Genet. 2008, 82:673-684.
14. Gamp A.C., Tanaka Y., Lüllmann-Rauch R., Wittke D., D'Hooge R., De Deyn P.P., Moser T., Maier H., Hartmann D., Reiss K., Illert A.L., von Figura K., Saftig P. LIMP-2/LGP85 deficiency causes ureteric pelvic junction obstruction, deafness and peripheral neuropathy in mice. Hum. Mol. Genet. 2003, 12:631-646.
15. Erickson A.H., Ginns E.I., Barranger J.A. Biosynthesis of the lysosomal enzyme glucocerebrosidase. J. Biol. Chem. 1985, 26:319-324.
16. Zachos C., Blanz J., Saftig P., Schwake M. A Critical Histidine Residue Within LIMP-2 Mediates pH Sensitive Binding to Its Ligand β-Glucocerebrosidase. Traffic 2012, 13:1113-1123.
17. Blanz J., Groth J., Zachos C., Wehling C., Saftig P., Schwake M. Disease-causing mutations within the lysosomal integral membrane protein type 2 (LIMP-2) reveal the nature of binding to its ligand beta-glucocerebrosidase. Hum. Mol. Genet. 2010, 19:563-572.
18. Balreira A., Gaspar P., Caiola D., Chaves J., Beirão I., Lima J.L., Azevedo J.E., Miranda M.C. A nonsense mutation in the LIMP-2 gene associated with progressive myoclonic epilepsy and nephrotic syndrome. Hum. Mol. Genet. 2008, 17:2238-2243.
19. Dardis A., Filocamo M., Grossi S., Ciana G., Franceschetti S., Dominissini S., Rubboli G., Di Rocco M., Bembi B. Biochemical and molecular findings in a patient with myoclonic epilepsy due to a mistarget of the beta-glucosidase enzyme. Mol. Genet. Metab. 2009, 97:309-311.
20. Hopfner F., Schormair B., Knauf F., Berthele A., Tölle T.R., Baron R., Maier C., Treede R.D., Binder A., Sommer C., Maihöfner C., Kunz W., Zimprich F., Heemann U., Pfeufer A., Näbauer M., Kääb S., Nowak B., Gieger C., Lichtner P., Trenkwalder C., Oexle K., Winkelmann J. Novel SCARB2 mutation in action myoclonus-renal failure syndrome and evaluation of SCARB2 mutations in isolated AMRF features. BMC Neurol. 2011, 27:134.
21. Dibbens L.M., Karakis I., Bayly M.A., Costello D.J., Cole A.J., Berkovic S.F. Mutation of SCARB2 in a patient with progressive myoclonus epilepsy and demyelinating peripheral neuropathy. Arch. Neurol. 2011, 68:812-813.
22. Costello D.J., Chiappa K.H., Siao P. Progressive myoclonus epilepsy with demyelinating peripheral neuropathy and preserved intellect: a novel syndrome. Arch. Neurol. 2009, 66:898-901.
23. Dibbens L.M., Michelucci R., Gambardella A., Andermann F., Rubboli G., Bayly M.A., Joensuu T., Vears D.F., Franceschetti S., Canafoglia L., Wallace R., Bassuk A.G., Power D.A., Tassinari C.A., Andermann E., Lehesjoki A.E., Berkovic S.F. SCARB2 mutations in progressive myoclonus epilepsy (PME) without renal failure. Ann. Neurol. 2009, 66:532-536.
24. Rubboli G., Franceschetti S., Berkovic S.F., Canafoglia L., Gambardella A., Dibbens L.M., Riguzzi P., Campieri C., Magaudda A., Tassinari C.A., Michelucci R. Clinical and neurophysiologic features of progressive myoclonus epilepsy without renal failure caused by SCARB2 mutations. Epilepsia 2011, 52:2356-2363.
25. Knipper M., Claussen C., Rüttiger L., Zimmermann U., Lüllmann-Rauch R., Eskelinen E.L., Schröder J., Schwake M., Saftig P. Deafness in LIMP2-deficient mice due to early loss of the potassium channel KCNQ1/KCNE1 in marginal cells of the stria vascularis. J. Physiol. 2006, 576:73-86.
26. Horoupian D.S., Ross R.T. Pigment variant of neuronal ceroid-lipofuscinosis (Kufs' disease). Can. J. Neurol. Sci. 1977, 4:67-75.
27. Andermann E., Andermann F., Carpenter S., Wolfe L.S., Nelson R., Patry G., Boileau J. Action myoclonus-renal failure syndrome: a previously unrecognized neurological disorder unmasked by advances in nephrology. Adv. Neurol. 1986, 43:87-103.
28. Rothdach A.J., Dietl T., Kümpfel T., Gottschalk M., Schumann E.M., Trenkwalder C. Familial myoclonus-renal failure syndrome. Nervenarzt 2001, 72:636-640.
29. Badhwar A., Berkovic S.F., Dowling J.P., Gonzales M., Narayanan S., Brodtmann A., Berzen L., Caviness J., Trenkwalder C., Winkelmann J., Rivest J., Lambert M., Hernandez-Cossio O., Carpenter S., Andermann F., Andermann E. Action myoclonus-renal failure syndrome: characterization of a unique cerebro-renal disorder. Brain 2004, 127:2173-2182.
30. Vadlamudi L., Vears D.F., Hughes A., Pedagogus E., Berkovic S.F. Action myoclonus-renal failure syndrome: a cause for worsening tremor in young adults. Neurology 2006, 67:1310-1311.
31. Eyal N., Firon N., Wilder S., Kolodny E.H., Horowitz M. Three unique base pair changes in a family with Gaucher disease. Hum. Genet. 1991, 87:328-332.
32. Ron I., Horowitz M. Intracellular cholesterol modifies the ERAD of glucocerebrosidase in Gaucher disease patients. Mol. Genet. Metab. 2008, 93:426-436.
33. Velayati A., DePaolo J., Gupta N., Choi J.H., Moaven N., Westbroek W., Goker-Alpan O., Goldin E., Stubblefield B.K., Kolodny E., Tayebi N., Sidransky E. A mutation in SCARB2 is a modifier in Gaucher disease. Hum. Mutat. 2011, 32:1232-1238.
34. Nielsen M.S., Madsen P., Christensen E.I., Nykjaer A., Gliemann J., Kasper D., Pohlmann R., Petersen C.M. The sortilin cytoplasmic tail conveys Golgi-endosome transport and binds the VHS domain of the GGA2 sorting protein. EMBO J. 2001, 20:2180-2190.
35. Braun J.E., Severson D.L. Lipoprotein lipase release from cardiac myocytes is increased by decavanadate but not insulin. Am. J. Physiol. 1992, 262:E663-E670.
36. Barbero P., Rovère C., De Bie I., Seidah N., Beaudet A., Kitabgi P. PC5-A-mediated processing of pro-neurotensin in early compartments of the regulated secretory pathway of PC5-transfected PC12 cells. J. Biol. Chem. 1998, 273:25339-25346.
37. Marcusson E.G., Horazdovsky B.F., Cereghino J.L., Gharakhanian E., Emr S.D. The sorting receptor for yeast vacuolar carboxypeptidase Y is encoded by the VPS10 gene. Cell 1994, 77:579-586.
38. Johnson K.F., Kornfeld S. A His-Leu-Leu sequence near the carboxyl terminus of the cytoplasmic domain of the cation-dependent mannose 6-phosphate receptor is necessary for the lysosomal enzyme sorting function. J. Biol. Chem. 1992, 267:17110-17115.
39. Johnson J.F., Kornfeld S. The cytoplasmic tail of the mannose 6-phosphate/insulin-like growth factor-II receptor has two signals for lysosomal enzyme sorting in the Golgi. J. Cell Biol. 1992, 119:249-257.
40. Ktistakis N.T., Brown H.A., Waters M.G., Sternweis P.C., Roth M.G. Evidence that phospholipase D mediates ADP ribosylation factor-dependent formation of Golgi coated vesicles. J. Cell Biol. 1996, 134:295-306.
41. Willnow T.E., Petersen C.M., Nykjaer A. VPS10P-domain receptors - regulators of neuronal viability and function. Nat. Rev. Neurosci. 2008, 9:899-909.
42. Munck Petersen C., Nielsen M.S., Jacobsen C., Tauris J., Jacobsen L., Gliemann J., Moestrup S.K., Madsen P. Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding. EMBO J. 1999, 18:595-604.
43. Nielsen M.S., Gustafsen C., Madsen P., Nyengaard J.R., Hermey G., Bakke O., Mari M., Schu P., Pohlmann R., Dennes A., Petersen C.M. Sorting by the cytoplasmic domain of the amyloid precursor protein binding receptor SorLA. Mol. Cell. Biol. 2007, 27:6842-6851.
44. Canuel M., Libin Y., Morales C.R. The interactomics of sortilin: an ancient lysosomal receptor evolving new functions. Histol. Histopathol. 2009 Apr, 24(4):481-492.
45. Klinger S.C., Glerup S., Raarup M.K., Mari M.C., Nyegaard M., Koster G., Prabakaran T., Nilsson S.K., Kjaergaard M.M., Bakke O., Nykjær A., Olivecrona G., Petersen C.M., Nielsen M.S. SorLA regulates the activity of lipoprotein lipase by intracellular trafficking. J. Cell Sci. 2011, 124:1095-1105.
46. Tauris J., Ellgaard L., Jacobsen C., Nielsen M.S., Madsen P., Thøgersen H.C., Gliemann J., Petersen C.M., Moestrup S.K. The carboxy-terminal domain of the receptor-associated protein binds to the Vps10p domain of sortilin. FEBS Lett. 1998, 429:27-30.
47. Kornfeld R., Kornfeld S. Assembly of asparagine-linked oligosaccharides. Annu. Rev. Biochem. 1985, 54:631-664.
48. Baldwin E.T., Bhat T.N., Gulnik S., Hosur M.V., Sowder R.C., Cachau R.E., Collins J., Silva A.M., Erickson J.W. Crystal structures of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug design. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:6796-6800.
49. Rigat B., Wang W., Leung A., Mahuran D.J. Two mechanisms for the recapture of extracellular GM2 activator protein: evidence for a major secretory form of the protein. Biochemistry 1997, 36:8325-8331.
50. Igdoura S.A., Rasky A., Morales C.R. Trafficking of sulfated glycoprotein-1 (prosaposin) to lysosomes or to the extracellular space in rat Sertoli cells. Cell Tissue Res. 1996, 283:385-394.
51. Gottesman M.M. Transformation-dependent secretion of a low molecular weight protein by murine fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 1978, 75:2767-2771.
52. Johnson L.M., Bankaitis V.A., Emr S.D. Distinct sequence determinants direct intracellular sorting and modification of a yeast vacuolar protease. Cell 1987, 48:875-885.
53. Valls L.A., Hunter C.P., Rothman J.H., Stevens T.H. Protein sorting in yeast: the localization determinant of yeast vacuolar carboxypeptidase Y resides in the propeptide. Cell 1987, 48:887-897.
54. Zeng J., Racicott J., Morales C.R. The inactivation of the sortilin gene leads to a partial disruption of prosaposin trafficking to the lysosomes. Exp. Cell Res. 2009, 315:3112-3124.
55. Zhu Y., Bujo H., Yamazaki H., Ohwaki K., Jiang M., Hirayama S., Kanaki T., Shibasaki M., Takahashi K., Schneider W.J., Saito Y. LR11, an LDL receptor gene family member, is a novel regulator of smooth muscle cell migration. Circ. Res. 2004, 94:752-758.
56. Dubé J.B., Johansen C.T., Hegele R.A. Sortilin: an unusual suspect in cholesterol metabolism: from GWAS identification to in vivo biochemical analyses, sortilin has been identified as a novel mediator of human lipoprotein metabolism. Bioessays 2011, 33:430-437.
57. Nykjaer A., Lee R., Teng K.K., Jansen P., Madsen P., Nielsen M.S., Jacobsen C., Kliemannel M., Schwarz E., Willnow T.E., Hempstead B.L., Petersen C.M. Sortilin is essential for proNGF-induced neuronal cell death. Nature 2004, 427:843-848.
58. Vaegter C.B., Jansen P., Fjorback A.W., Glerup S., Skeldal S., Kjolby M., Richner M., Erdmann B., Nyengaard J.R., Tessarollo L., Lewin G.R., Willnow T.E., Chao M.V., Nykjaer A. Sortilin associates with Trk receptors to enhance anterograde transport and neurotrophin signaling. Nat. Neurosci. 2011, 14:54-61.
59. Hu F., Padukkavidana T., Vægter C.B., Brady O.A., Zheng Y., Mackenzie I.R., Feldman H.H., Nykjaer A., Strittmatter S.M. Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron 2010, 68:654-667.
60. Shi J., Kandror K.V. The luminal Vps10p domain of sortilin plays the predominant role in targeting to insulin-responsive Glut4-containing vesicles. J. Biol. Chem. 2007, 282:9008-9016.
61. Maeda S., Nobukuni T., Shimo-Onoda K., Hayashi K., Yone K., Komiya S., Inoue I. Sortilin is upregulated during osteoblastic differentiation of mesenchymal stem cells and promotes extracellular matrix mineralization. J. Cell. Physiol. 2002, 193:73-79.
62. Kulterer B., Friedl G., Jandrositz A., Sanchez-Cabo F., Prokesch A., Paar C., Scheideler M., Windhager R., Preisegger K.H., Trajanoski Z. Gene expression profiling of human mesenchymal stem cells derived from bone marrow during expansion and osteoblast differentiation. BMC Genomics 2007, 8:70.
63. Nilsson S.K., Christensen S., Raarup M.K., Ryan R.O., Nielsen M.S., Olivecrona G. Endocytosis of apolipoprotein A-V by members of the low density lipoprotein receptor and the VPS10p domain receptor families. J. Biol. Chem. 2008, 283:25920-25927.
64. Samani N.J., Erdmann J., Hall A.S., Hengstenberg C., Mangino M., Mayer B., Dixon R.J., Meitinger T., Braund P., Wichmann H.E., Barrett J.H., König I.R., Stevens S.E., Szymczak S., Tregouet D.A., Iles M.M., Pahlke F., Pollard H., Lieb W., Cambien F., Fischer M., Ouwehand W., Blankenberg S., Balmforth A.J., Baessler A., Ball A.S.G., Strom T.M., Braenne I., Gieger C., Deloukas P., Tobin M.D., Ziegler A., Thompson J.R., Schunkert H. WTCCC and the Cardiogenics consortium, genomewide association analysis of coronary artery disease. N. Engl. J. Med. 2007, 357:443-453.
65. Linsel-Nitschke P., Samani N.J., Schunkert H. Sorting out cholesterol and coronary artery disease. N. Engl. J. Med. 2010, 363:2462-2463.
66. Musunuru K., Strong A., Frank-Kamenetsky M., Lee N.E., Ahfeldt T., Sachs K.V., Li X., Li H., Kuperwasser N., Ruda V.M., Pirruccello J.P., Muchmore B., Prokunina-Olsson L., Hall J.L., Schadt E.E., Morales C.R., Lund-Katz S., Phillips M.C., Wong J., Cantley W., Racie T., Ejebe K.G., Orho-Melander M., Melander O., Koteliansky V., Fitzgerald K., Krauss R.M., Cowan C.A., Kathiresan S., Rader D.J. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 2010, 466:714-719.
67. Kjolby M., Andersen O.M., Breiderhoff T., Fjorback A.W., Pedersen K.M., Madsen P., Jansen P., Heeren J., Willnow T.E., Nykjaer A. Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export. Cell Metab. 2010, 12:213-223.
68. Shi J., Kandror K.V. Sortilin is essential and sufficient for the formation of Glut4 storage vesicles in 3T3-L1 adipocytes. Dev. Cell 2005, 9:99-108.
69. Mufson E.J., Wuu J., Counts S.E., Nykjaer A. Preservation of cortical sortilin protein levels in MCI and Alzheimer's disease. Neurosci. Lett. 2010, 471:129-133.
70. Teng H.K., Teng K.K., Lee R., Wright S., Tevar S., Almeida R.D., Kermani P., Torkin R., Chen Z.Y., Lee F.S., Kraemer R.T., Nykjae A., Hempstead B.L. ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J. Neurosci. 2005, 25:5455-5463.
71. Wähe A., Kasmapour B., Schmaderer C., Liebl D., Sandhoff K., Nykjaer A., Griffiths G., Gutierrez M.G. Golgi-to-phagosome transport of acid sphingomyelinase and prosaposin is mediated by sortilin. J. Cell Sci. 2010, 123:2502-2511.
72. Kathiresan S., Melander O., Guiducci C., Surti A., Burtt N.P., Rieder M.J., Cooper G.M., Roos C., Voight B.F., Havulinna A.S., Wahlstrand B., Hedner T., Corella D., Tai E.S., Ordovas J.M., Berglund G., Vartiainen E., Jousilahti P., Hedblad B., Taskinen M.R., Newton-Cheh C., Salomaa V., Peltonen L., Groop L., Altshuler D.M., Orho-Melander M. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet. 2008, 40:189-197.
73. Kathiresan S., Willer C.J., Peloso G.M., Demissie S., Musunuru K., Schadt E.E., Kaplan L., Bennett D., Li Y., Tanaka T., Voight B.F., Bonnycastle L.L., Jackson A.U., Crawford G., Surti A., Guiducci C., Burtt N.P., Parish S., Clarke R., Zelenika D., Kubalanza K.A., Morken M.A., Scott L.J., Stringham H.M., Galan P., Swift A.J., Kuusisto J., Bergman R.N., Sundvall J., Laakso M., Ferrucci L., Scheet P., Sanna S., Uda M., Yang Q., Lunetta K.L., Dupuis J., de Bakker P.I., O'Donnell C.J., Chambers J.C., Kooner J.S., Hercberg S., Meneton P., Lakatta E.G., Scuteri A., Schlessinger D., Tuomilehto J., Collins F.S., Groop L., Altshuler D., Collins R., Lathrop G.M., Melander O., Salomaa V., Peltone L., Orho-Melander M., Ordovas J.M., Boehnke M., Abecasis G.R., Mohlke K.L., Cupples L.A. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat. Genet. 2009, 41:56-65.
74. Tall A.R., Ai D. Sorting out sortilin. Circ. Res. 2011, 108:158-160.
75. Belzil V.V., André-Guimont C., Atallah M.R., Daoud H., Dupré N., Bouchard J.P., Camu W., Dion P.A., Rouleau G.A. Analysis of the SORT1 gene in familial amyotrophic lateral sclerosis. Neurobiol. Aging 2012, 33:1845.e7-9.
76. Kabashi E., Valdmanis P.N., Dion P., Spiegelman D., McConkey B.J., Vande Velde C., Bouchard J.P., Lacomblez L., Pochigaeva K., Salachas F., Pradat P.F., Camu W., Meininger V., Dupre N., Rouleau G.A. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 2008, 40:572-574.
77. Sreedharan J., Blair I.P., Tripathi V.B., Hu X., Vance C., Rogelj B., Ackerley S., Durnall J.C., Williams K.L., Buratti E., Baralle F., de Belleroche J., Mitchell J.D., Leigh P.N., Al-Chalabi A., Miller C.C., Nicholson G., Shaw C.E. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008, 319:1668-1672.
78. Kwiatkowski T.J., Bosco D.A., Leclerc A.L., Tamrazian E., Vanderburg C.R., Russ C., Davis A., Gilchrist J., Kasarskis E.J., Munsat T., Valdmanis P., Rouleau G.A., Hosler B.A., Cortelli P., de Jong P.J., Yoshinaga Y., Haines J.L., Pericak-Vance M.A., Yan J., Ticozzi N., Siddique T., McKenna-Yasek D., Sapp P.C., Horvitz H.R., Landers J.E., Brown R.H. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009, 323:1205-1208.
79. Vance C., Rogelj B., Hortobágyi T., De Vos K.J., Nishimura A.L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P., Ganesalingam J., Williams K.L., Tripathi V., Al-Saraj S., Al-Chalabi A., Leigh P.N., Blair I.P., Nicholson G., de Belleroche J., Gallo J.M., Miller C.C., Shaw C.A. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009, 323:1208-1211.
80. Broustal O., Camuzat A., Guillot-Noel L., Guy N., Millecamps S., Deffond D., Lacomblez L., Golfier V., Hannequin D., Salachas F., Camu W., Didic M., Dubois B., Meininger V., Le Ber I., Brice A. French clinical and genetic research network on FTD/FTD-MND, FUS mutations in frontotemporal lobar degeneration with amyotrophic lateral sclerosis. J. Alzheimers Dis. 2010, 22:765-769.
81. Huey E.D., Ferrari R., Moreno J.H., Jensen C., Morris C.M., Potocnik F., Kalaria R.N., Tierney M., Wassermann E.M., Hardy J., Grafman J., Momeni P. FUS and TDP43 genetic variability in FTD and CBS. Neurobiol. Aging 2012, 33:1016.e9-17.
82. Polymenidou M., Lagier-Tourenne C., Hutt K.R., Huelga S.C., Moran J., Liang T.Y., Ling S.C., Sun E., Wancewicz E., Mazur C., Kordasiewicz H., Sedaghat Y., Donohue J.P., Shiue L., Bennett C.F., Yeo G.W., Cleveland D.W. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat. Neurosci. 2011, 14:459-468.
83. Mahuran D.J. The GM2 activator protein, its roles as a co-factor in GM2 hydrolysis and as a general glycolipid transport protein. Biochim. Biophys. Acta 1998, 1393:1-18.
84. Hermans-Borgmeyer I., Hermey G., Nykjaer A., Schaller C. Expression of the 100-kDa neurotensin receptor sortilin during mouse embryonal development. Brain Res. Mol. Brain Res. 1999, 65:216-219.
85. Mazella J., Vincent J.P. Internalization and recycling properties of neurotensin receptors. Peptides 2006, 27:2488-2492.
86. Chen B., Rigat B., Curry C., Mahuran D.J. Structure of the GM2A gene: identification of an exon 2 nonsense mutation and a naturally occurring transcript with an in-frame deletion of exon 2. Am. J. Hum. Genet. 1999, 65:77-87.
87. Stevens R.L., Fluharty A.L., Kihara H., Kaback M.M., Shapiro L.J., Marsh B., Sandhoff K., Fischer G. Cerebroside sulfatase activator deficiency induced metachromatic leukodystrophy. Am. J. Hum. Genet. 1981, 33:900-906.
88. Christomanou H., Aignesberger A., Linke R.P. Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro. Absence of one of them in a human Gaucher disease variant. Biol. Chem. Hoppe Seyler 1986, 367:879-890.
89. Ramirez-Montealegre D., Rothberg P.G., Pearce D.A. Another disorder finds its gene. Brain 2006, 129:1353-1356.
90. Dhami R., Passini M.A., Schuchman E.H. Identification of novel biomarkers for Niemann-Pick disease using gene expression analysis of acid sphingomyelinase knockout mice. Mol. Ther. 2006, 13:556-564.
91. Brady R.O., Kanfer J.N., Shapiro D. Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease. Biochem. Biophys. Res. Commun. 1965, 18:221-225.
92. Reitman M.L., Varki A., Kornfeld S. Fibroblasts from patients with I-cell disease and pseudo-Hurler polydystrophy are deficient in uridine 5'-diphosphate-N-acetylglucosamine: glycoprotein N-acetylglucosaminylphosphotransferase activity. J. Clin. Invest. 1981, 67:1574-1579.
93. Honey N.K., Mueller O.T., Little L.E., Miller A.L., Shows T.B. Mucolipidosis III is genetically heterogeneous. Proc. Natl. Acad. Sci. U. S. A. 1982, 79:7420-7424.
94. Waheed A., Gottschalk S., Hille A., Krentler C., Pohlmann R., Braulke T., Hauser H., Geuze H., von Figura K. Human lysosomal acid phosphatase is transported as a transmembrane protein to lysosomes in transfected baby hamster kidney cells. EMBO J. 1988, 7:2351-2358.
95. Obermüller S., Kiecke C., von Figura K., Höning S. The tyrosine motifs of Lamp 1 and LAP determine their direct and indirect targetting to lysosomes. J. Cell Sci. 2002, 115:185-194.
96. Peters C., Braun M., Weber B., Wendland M., Schmidt B., Pohlmann R., Waheed A., von Figura K. Targeting of a lysosomal membrane protein: a tyrosine-containing endocytosis signal in the cytoplasmic tail of lysosomal acid phosphatase is necessary and sufficient for targeting to lysosomes. EMBO J. 1990, 9:3497-3506.
97. Pohlmann R., Krentler C., Schmidt B., Schröder W., Lorkowski G., Culley J., Mersmann G., Geier C., Waheed A., Gottschalk S. Human lysosomal acid phosphatase: cloning, expression and chromosomal assignment. EMBO J. 1988, 7:2343-2350.